{"id":"https://openalex.org/W4409688942","doi":"https://doi.org/10.1158/1538-7445.am2025-3215","title":"Abstract 3215: Cystatin F changes in melanoma patients during therapy with immune checkpoint inhibitors","display_name":"Abstract 3215: Cystatin F changes in melanoma patients during therapy with immune checkpoint inhibitors","publication_year":2025,"publication_date":"2025-04-21","ids":{"openalex":"https://openalex.org/W4409688942","doi":"https://doi.org/10.1158/1538-7445.am2025-3215"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2025-3215","doi":"https://doi.org/10.1158/1538-7445.am2025-3215","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2025-3215","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103190680","display_name":"Milica Peri\u0161i\u0107 Nanut","orcid":"https://orcid.org/0000-0003-2314-2733","observed_orcids":["https://orcid.org/0000-0003-2314-2733"]},"institutions":[{"id":"https://openalex.org/I3006985408","display_name":"Jo\u017eef Stefan Institute","ror":"https://ror.org/05060sz93","country_code":"SI","type":"facility","lineage":["https://openalex.org/I3006985408"]}],"countries":["SI"],"is_corresponding":false,"raw_author_name":"Milica M. Perisic Nanut","raw_affiliation_strings":["1Jozef Stefan Institute, Ljubljana, Slovenia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Jozef Stefan Institute, Ljubljana, Slovenia;","institution_ids":["https://openalex.org/I3006985408"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001598505","display_name":"Emanuela Senjor","orcid":"https://orcid.org/0000-0002-1040-5365","observed_orcids":["https://orcid.org/0000-0002-1040-5365"]},"institutions":[{"id":"https://openalex.org/I3006985408","display_name":"Jo\u017eef Stefan Institute","ror":"https://ror.org/05060sz93","country_code":"SI","type":"facility","lineage":["https://openalex.org/I3006985408"]}],"countries":["SI"],"is_corresponding":false,"raw_author_name":"Emanuela Senjor","raw_affiliation_strings":["1Jozef Stefan Institute, Ljubljana, Slovenia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Jozef Stefan Institute, Ljubljana, Slovenia;","institution_ids":["https://openalex.org/I3006985408"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013032782","display_name":"Tanja Mesti","orcid":"https://orcid.org/0000-0002-6129-532X","observed_orcids":["https://orcid.org/0000-0002-6129-532X"]},"institutions":[{"id":"https://openalex.org/I3019592416","display_name":"Institute of Oncology Ljubljana","ror":"https://ror.org/00y5zsg21","country_code":"SI","type":"facility","lineage":["https://openalex.org/I3019592416"]}],"countries":["SI"],"is_corresponding":false,"raw_author_name":"Tanja Mesti","raw_affiliation_strings":["2Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia;","institution_ids":["https://openalex.org/I3019592416"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026633217","display_name":"Simona Miceska","orcid":"https://orcid.org/0000-0003-1889-1991","observed_orcids":["https://orcid.org/0000-0003-1889-1991"]},"institutions":[{"id":"https://openalex.org/I3019592416","display_name":"Institute of Oncology Ljubljana","ror":"https://ror.org/00y5zsg21","country_code":"SI","type":"facility","lineage":["https://openalex.org/I3019592416"]}],"countries":["SI"],"is_corresponding":false,"raw_author_name":"Simona Miceska","raw_affiliation_strings":["3Department of Medical Oncology, Institute of Oncology Ljubljana, Department of Medical Oncology, Institute of Oncology Ljubljana, , Ljubljana, Slovenia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Department of Medical Oncology, Institute of Oncology Ljubljana, Department of Medical Oncology, Institute of Oncology Ljubljana, , Ljubljana, Slovenia;","institution_ids":["https://openalex.org/I3019592416"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067298588","display_name":"Janja Ocvirk","orcid":"https://orcid.org/0000-0002-5235-2054","observed_orcids":["https://orcid.org/0000-0002-5235-2054"]},"institutions":[{"id":"https://openalex.org/I3019592416","display_name":"Institute of Oncology Ljubljana","ror":"https://ror.org/00y5zsg21","country_code":"SI","type":"facility","lineage":["https://openalex.org/I3019592416"]}],"countries":["SI"],"is_corresponding":false,"raw_author_name":"Janja Ocvirk","raw_affiliation_strings":["2Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia;","institution_ids":["https://openalex.org/I3019592416"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5059675124","display_name":"Janko Kos","orcid":"https://orcid.org/0000-0002-4228-3518","observed_orcids":["https://orcid.org/0000-0002-4228-3518"]},"institutions":[{"id":"https://openalex.org/I153976015","display_name":"University of Ljubljana","ror":"https://ror.org/05njb9z20","country_code":"SI","type":"education","lineage":["https://openalex.org/I153976015"]}],"countries":["SI"],"is_corresponding":false,"raw_author_name":"Janko Kos","raw_affiliation_strings":["4Department of Pharmaceutical Biology, Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Department of Pharmaceutical Biology, Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia","institution_ids":["https://openalex.org/I153976015"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"85","issue":"8_Supplement_1","first_page":"3215","last_page":"3215"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cystatin-f","display_name":"cystatin F","score":0.9940000176429749},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.8399999737739563},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":1.0},{"id":"https://openalex.org/keywords/cytotoxic-t-lymphocytes","display_name":"cytotoxic T lymphocytes","score":0.902999997138977},{"id":"https://openalex.org/keywords/pd-1","display_name":"PD-1","score":0.878000020980835},{"id":"https://openalex.org/keywords/interferon-gamma","display_name":"interferon-gamma","score":0.7570000290870667},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.9279999732971191},{"id":"https://openalex.org/keywords/treatment-response-biomarkers","display_name":"treatment response biomarkers","score":0.5870000123977661},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.7630000114440918},{"id":"https://openalex.org/keywords/immunotherapy-resistance","display_name":"immunotherapy resistance","score":0.6399999856948853},{"id":"https://openalex.org/keywords/hyperprogression","display_name":"hyperprogression","score":0.6919999718666077},{"id":"https://openalex.org/keywords/pseudoprogression","display_name":"pseudoprogression","score":0.8880000114440918},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.609000027179718},{"id":"https://openalex.org/keywords/first-line-immunotherapy","display_name":"first-line immunotherapy","score":0.6660000085830688},{"id":"https://openalex.org/keywords/tumor-infiltrating-cells","display_name":"tumor-infiltrating cells","score":0.4440000057220459}],"concepts":[{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.7020998001098633},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6711875200271606},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.5778864622116089},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4803422689437866},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.446757048368454},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3568812608718872},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3295094966888428},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.24059823155403137}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2025-3215","doi":"https://doi.org/10.1158/1538-7445.am2025-3215","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2025-3215","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1991879524","https://openalex.org/W2171435634","https://openalex.org/W2066581032","https://openalex.org/W2079364398","https://openalex.org/W2079772486","https://openalex.org/W4248678482","https://openalex.org/W2124622370","https://openalex.org/W2468522164","https://openalex.org/W4220823109","https://openalex.org/W3112004363"],"abstract_inverted_index":{"Abstract":[0],"Although":[1],"immune":[2,353],"checkpoint":[3,354],"inhibitors":[4,355],"(ICI)":[5],"have":[6,116,181],"achieved":[7],"undeniable":[8],"success":[9],"in":[10,103,143,151,155,166,194,267,288,290,301,308,347],"the":[11,95,152,188,228,233,243,261,294,360],"treatment":[12,72,111,179,323,326],"of":[13,34,84,98,128,131,158,168,230,245,264,298,359],"metastatic":[14],"melanoma,":[15],"primary":[16],"and":[17,79,112,146,172,192,207,237,242,274,310,324],"secondary":[18],"resistance":[19],"to":[20,24,37,62,76,94,108,140,162,178,224],"ICI":[21],"therapy":[22,211,351],"continues":[23],"pose":[25],"a":[26,90,118,124,318],"significant":[27],"challenge":[28],"for":[29,320,363],"melanoma":[30,171,202,279,348],"patients.":[31],"Around":[32],"40-60%":[33],"patients":[35,169,199,311,349],"respond":[36],"immunotherapy,":[38],"achieving":[39],"long-term":[40],"benefits,":[41],"but":[42,149],"over":[43],"two-thirds":[44],"experience":[45,64],"immune-related":[46],"adverse":[47],"events":[48],"(irAEs)":[49],"with":[50,66,170,176,187,200,212,312,352],"ICIs.":[51,213],"About":[52],"10%":[53],"show":[54],"pseudoprogression,":[55],"marked":[56],"by":[57],"transient":[58],"inflammation,":[59],"while":[60],"up":[61,223],"30%":[63],"hyperprogression":[65],"rapid":[67],"cancer":[68,153],"advancement.":[69],"Despite":[70],"irAEs,":[71,313],"interruption":[73],"often":[74],"leads":[75],"better":[77],"outcomes":[78],"prolonged":[80],"survival.":[81],"The":[82],"lack":[83],"clinically":[85],"validated":[86],"predictive":[87],"biomarkers":[88],"remains":[89],"major":[91],"factor":[92],"contributing":[93],"unpredictable":[96],"effects":[97],"immunotherapy.":[99],"Implementing":[100],"biological":[101],"markers":[102,246],"clinical":[104],"practice":[105],"is":[106],"essential":[107],"enhance":[109],"personalized":[110,322],"predict":[113],"responses.":[114,327],"We":[115,259],"identified":[117],"protease":[119],"inhibitor":[120],"cystatin":[121,183,265,285,299],"F":[122,184,266,286,300,345],"as":[123,317],"potent":[125],"down":[126],"regulator":[127],"cytotoxic":[129,132],"efficacy":[130],"T":[133],"lymphocytes":[134],"(CTLs).":[135],"Its":[136],"expression":[137,175,191,244,287,307],"was":[138,254],"shown":[139],"be":[141],"increased":[142],"hypo":[144],"responsive":[145],"exhausted":[147],"CTLs":[148,167,197,253,304],"also":[150],"tissue":[154,269,280],"several":[156],"types":[157],"cancer.":[159],"In":[160],"order":[161],"elucidate":[163],"its":[164,174,315],"role":[165],"correlation":[173],"response":[177],"we":[180],"examined":[182],"expression,":[185],"along":[186],"CTL":[189],"PD-1":[190],"IFN\u03b3":[193],"peripheral":[195,302],"blood":[196,249,303],"form":[198],"advanced":[201],"(TNM":[203],"classification,":[204],"stage":[205],"IIID":[206],"IV)":[208],"receiving":[209],"first-line":[210],"Study-specific":[214],"data":[215],"were":[216],"collected":[217],"at":[218,232],"three":[219],"different":[220],"time":[221],"points:":[222],"4":[225],"weeks":[226],"before":[227],"start":[229],"treatment,":[231],"12th":[234],"(+/\u22122":[235,240],"weeks)":[236,241],"28th":[238],"week":[239],"on":[247,277],"whole":[248],"preparations":[250],"or":[251],"isolated":[252],"analysed":[255],"using":[256,270],"flow":[257],"cytometry.":[258],"characterized":[260],"cellular":[262],"sources":[263],"tumor":[268,295],"multicolor":[271],"immunofluorescence":[272],"staining":[273],"confocal":[275],"analysis":[276],"formalin-fixed":[278],"samples.":[281],"Our":[282],"findings":[283],"reveal":[284],"predominantly":[289],"non-lymphoid":[291],"cells":[292],"within":[293],"microenvironment.":[296],"Analysis":[297],"shows":[305],"higher":[306],"non-responders":[309],"suggesting":[314],"potential":[316],"marker":[319],"enhancing":[321],"predicting":[325],"Citation":[328],"Format:":[329],"Milica":[330],"M.":[331],"Perisic":[332],"Nanut,":[333],"Emanuela":[334],"Senjor,":[335],"Tanja":[336],"Mesti,":[337],"Simona":[338],"Miceska,":[339],"Janja":[340],"Ocvirk,":[341],"Janko":[342],"Kos.":[343],"Cystatin":[344],"changes":[346],"during":[350],"[abstract].":[356],"In:":[357],"Proceedings":[358],"American":[361],"Association":[362],"Cancer":[364,381],"Research":[365],"Annual":[366],"Meeting":[367],"2025;":[368],"Part":[369],"1":[370],"(Regular":[371],"Abstracts);":[372],"2025":[373],"Apr":[374],"25-30;":[375],"Chicago,":[376],"IL.":[377],"Philadelphia":[378],"(PA):":[379],"AACR;":[380],"Res":[382],"2025;85(8_Suppl_1):Abstract":[383],"nr":[384],"3215.":[385]},"counts_by_year":[],"updated_date":"2026-09-24T07:57:37.273135","created_date":"2025-10-10T00:00:00"}